BioCentury Inc.’s Post

Discovery through perturbation: taking causality into your own hands. A company's experimental setup and scale shape the type of AI it uses and questions it can ask

We cannot continue to ignore the heterogeneity in ALS. The tools exist, it’s time to embrace them. Long-read sequencing is just one of the force-multipliers at hand, argues PAACS Invest Co-Chair Masha Stromme in a BioCentury Guest Commentary

BioCentury Washington Editor Steve Usdin joined BioIndustry Association (BIA)'s Steve Bates OBE FMedSci and Goodwin's Matt Wetzel for a panel discussion on the impact of US politics on the biotech sector, including insights into the #InflationReductionAct and the #Biosecure bill. Hear how these developments could shape the future for UK biotech: https://lnkd.in/ddHGmAJC

On this week's #BioCenturyThisWeek podcast: ➤ Stephen Hansen discusses why buysiders and bankers believe biotech is primed for growth after three years of a bear market. ➤ Steve Usdin critiques the FDA's planned reforms for advisory committees, calling for more impactful changes, and shares insights from CMS’s anti-amyloid decision. ➤ Joshua Berlin previews the upcoming #BioCenturyChinaSummit in Shanghai, which will focus on reinventing China strategies. Tune in on your favorite podcast platform: https://lnkd.in/gcbtZrvR

Baker and DeepMind Nobel: two sides of a computational protein coin

How to establish causality via patient observation: Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal

Causal biology in the age of big data: Whether companies anchor a new target’s relevance in large-scale patient data or human cell perturbation is a key question for companies doing target discovery.

After 3 years of down #biotech markets, BioCentury's @StephenPHansen finds in his 4Q24 Public Markets Preview that investors believe the sector has the necessary ingredients for a return to growth and outperformance

I-SPY 2.2 is working. Why aren’t others replicating the design? Initial data show the latest I-SPY trial can uncover less toxic neoadjuvant breast cancer therapies. BioCentury explores the benefits and challenges of the study's design

@US_FDA's proposals for optimizing advisory committee meetings are too little, too late, argues Washington Editor @SteveUsdin1 in an Editor's Commentary